Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Akari Therapeutics Plc (AKTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 6-K Quarterly results
08/18/2023 6-K Quarterly results
08/15/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Akari Therapeutics, Plc Announces ADS Ratio Change"
08/02/2023 6-K Quarterly results
07/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation"
07/25/2023 6-K Quarterly results
07/19/2023 6-K Quarterly results
07/13/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA"
07/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy"
07/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Amended Articles of Association of Akari Therapeutics, Plc",
"Amended Articles of Association of Akari Therapeutics, Plc"
07/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation"
07/05/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Akari Therapeutics Appoints Industry Veteran Wa’ el Hashad to Board of Directors"
06/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
05/05/2023 6-K Quarterly results
05/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
05/01/2023 6-K Quarterly results
04/25/2023 6-K Quarterly results
03/31/2023 6-K Quarterly results
03/29/2023 6-K Quarterly results
03/28/2023 6-K Quarterly results
03/13/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
02/13/2023 6-K Quarterly results
11/10/2022 6-K Quarterly results
11/08/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer"
10/28/2022 6-K Quarterly results
09/27/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "​",
"Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2022",
"​",
"​"
09/14/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Opinion of McDermott Will & Emery UK LLP",
"Form of Securities Purchase Agreement between Akari Therapeutics, Plc and the investors listed therein",
"Form of Series A Warrant to be issued by Akari Therapeutics, Plc on September 14, 2022",
"Form of Series B Warrant to be issued by Akari Therapeutics, Plc on September 14, 2022",
"Akari Therapeutics Announces $12.75 Million Registered Direct Offering"
08/01/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Akari Therapeutics Narrows Pipeline Focus"
07/29/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy · Positive results from recent pre-clinical studies support the potential of long-acting PASylated â nomacopan to advance toward IND/IMPD for clinical trials in geographic atrophy in dry age-related macular degeneration , a disease with no approved treatments · New PK measurements indicate the half-life within the eye of intravitreally injected early generation PAS-nomacopan in a standard ophthalmic pre-clinical model can be accurately predicted; results support Akari’ s continuing work to develop new generation PAS-nomacopan that may enable dosing in..."
07/20/2022 6-K Quarterly results
07/07/2022 6-K Quarterly results
07/05/2022 6-K Quarterly results
06/15/2022 6-K Quarterly results
06/06/2022 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy